There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Xeris Pharmaceuticals (XERS) and NGM Biopharmaceuticals (NGM) with bullish sentiments.
Xeris Pharmaceuticals (XERS)
In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Xeris Pharmaceuticals, with a price target of $14.00. The company’s shares closed last Thursday at $4.09.
According to TipRanks.com, Yang ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -8.1% and a 32.7% success rate. Yang covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Nektar Therapeutics, and Abeona Therapeutics.
Currently, the analyst consensus on Xeris Pharmaceuticals is a Moderate Buy with an average price target of $12.50.
See today’s analyst top recommended stocks >>
NGM Biopharmaceuticals (NGM)
In a report released today, Mayank Mamtani from B.Riley Financial maintained a Buy rating on NGM Biopharmaceuticals, with a price target of $38.00. The company’s shares closed last Thursday at $25.71.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 33.0% and a 53.4% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals, and Spectrum Pharmaceuticals.
Currently, the analyst consensus on NGM Biopharmaceuticals is a Strong Buy with an average price target of $34.50, a 34.2% upside from current levels. In a report issued on December 9, Raymond James also initiated coverage with a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
